FDAsafety guidance83% confidence
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to image-guided therapy companies.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Image-Guided Therapy
- Sub-indication
- General
Related signal: Study on Image-Guided Cancer Treatments Using Spectral Angio-CT